Martin Storr, MD

Affiliations: 
Medicine University of Calgary, Calgary, Alberta, Canada 
Google:
"Martin Storr"
Mean distance: 106866
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Kienzl M, Storr M, Schicho R. (2020) Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. Clinical and Translational Gastroenterology
Fabisiak A, Włodarczyk M, Fabisiak N, et al. (2019) Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis. Journal of Gastrointestinal and Liver Diseases : Jgld. 28: 473-481
Salaga M, Binienda A, Tichkule RB, et al. (2019) Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43]. European Journal of Pharmacology. 172656
Andrews CN, Devlin SM, Le Foll B, et al. (2019) Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders. Journal of the Canadian Association of Gastroenterology. 2: 37-43
Szymaszkiewicz A, Storr M, Fichna J, et al. (2018) Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. e13526
Salaga M, Binienda A, Tichkule RB, et al. (2018) The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. European Journal of Pharmacology
Szymaszkiewicz A, Zielinska M, Li K, et al. (2018) Novel derivatives of 1,2,3-triazole, cannabinoid-1 receptor ligands modulate gastrointestinal motility in mice. Naunyn-Schmiedeberg's Archives of Pharmacology
Binienda A, Storr M, Fichna J, et al. (2017) Efficacy and safety of serotonin receptor ligands in the treatment of irritable bowel syndrome: a review. Current Drug Targets
Fabisiak A, Włodarczyk J, Fabisiak N, et al. (2017) Targeting Histamine Receptors in Irritable Bowel Syndrome: A Critical Appraisal. Journal of Neurogastroenterology and Motility
Wasilewski A, Lewandowska U, Mosinska P, et al. (2017) Cannabinoid Receptor Type 1 and mu-Opioid Receptor Polymorphisms Are Associated With Cyclic Vomiting Syndrome. The American Journal of Gastroenterology
See more...